Medicare Enrolled
Dr. Ian Horkheimer, MD
Optician · Little Silver, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Horkheimer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Horkheimer?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Horkheimer
Dr. Ian Horkheimer is an optician specialist in Little Silver, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Horkheimer performed 40,224 Medicare services across 3,122 unique beneficiaries.
Between the years covered by Open Payments, Dr. Horkheimer received a total of $551 from 15 pharmaceutical and/or device companies across 25 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Horkheimer is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 2% volume in NJ
$551 industry payments
Medicare Practice Summary
Medicare Utilization ↗40,224
Medicare services
Top 2% in NJ for optician
3,122
Unique beneficiaries
$27
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,011 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 10,900 | $43 | $133 |
| Anti-nausea injection (aprepitant) | 7,670 | $1 | $7 |
| Iron infusion (Monoferric) | 4,900 | $17 | $67 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,028 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 2,580 | $18 | $59 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,778 | $8 | $32 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,465 | $8 | $18 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,353 | $104 | $230 |
| Anti-nausea injection (Aloxi/palonosetron) | 970 | $1 | $98 |
| Anti-nausea injection (ondansetron/Zofran) | 746 | $0 | $2 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
628 | $25 | $125 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
588 | $108 | $857 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
543 | $113 | $557 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
318 | $66 | $158 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
251 | $53 | $261 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
246 | $11 | $81 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
225 | $150 | $310 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
206 | $73 | $152 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
177 | $7 | $340 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
171 | $13 | $84 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
158 | $1 | $5 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
130 | $63 | $195 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
127 | $1 | $13 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
119 | $57 | $256 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
104 | $17 | $77 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
104 | $29 | $127 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
104 | $2 | $14 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
99 | $24 | $122 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
90 | $99 | $231 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
76 | $145 | $419 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
75 | $1 | $16 |
| New patient office visit, complex (60-74 min) | 67 | $182 | $440 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
63 | $11 | $61 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
54 | $28 | $219 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
38 | $4 | $26 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
25 | $127 | $351 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
18 | $72 | $172 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
17 | $33 | $56 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
13 | $236 | $513 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
16.7% high complexity
68.7% medium
14.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$551
Total received (2018-2024)
Avg $79/year across 7 years
Bottom 43% in NJ for optician
15
Companies
25
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$416 (75.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$135 (24.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$164
2023
$50
2022
$52
2021
$25
2020
$15
2019
$190
2018
$55
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Gilead Sciences, Inc.
$48
Regeneron Healthcare Solutions, Inc.
$34
Acrotech Biopharma Inc.
$32
Lilly USA, LLC
$22
ABBVIE INC.
$15
Celgene Corporation
$14
Top 3 companies account for 68.9% of 2024 payments
All-time payments by company (2018-2024) ›
Incyte Corporation
$125
Janssen Biotech, Inc.
$97
Gilead Sciences, Inc.
$92
Regeneron Healthcare Solutions, Inc.
$34
Acrotech Biopharma Inc.
$32
E.R. Squibb & Sons, L.L.C.
$27
Bayer HealthCare Pharmaceuticals Inc.
$24
Lilly USA, LLC
$22
Alexion Pharmaceuticals, Inc.
$16
Genentech USA, Inc.
$15
ABBVIE INC.
$15
Celgene Corporation
$14
Amgen Inc.
$13
AstraZeneca Pharmaceuticals LP
$13
Takeda Pharmaceuticals U.S.A., Inc.
$12
Top 3 companies account for 57.0% of all-time payments
Associated products mentioned in payments ›
Aliqopa · DARZALEX · ELAHERE · ERLEADA · EXKIVITY · Erleada · GAZYVA · IMFINZI · JAKAFI · Kyprolis · LIBTAYO · OPDIVO · OPDUALAG · REBLOZYL · RYZNEUTA · SOLIRIS · Trodelvy
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (76%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Opticians within 10 mi
6,765
Per 100K population
1051.1
County median income
$122,727
Nearest hospital
RIVERVIEW MEDICAL CENTER
2.8 mi
2.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Horkheimer is a mixed practice specialist, with above-average Medicare volume (top 2% in NJ), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Horkheimer experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Horkheimer performed 10,900 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Horkheimer receive payments from pharmaceutical companies?
Yes. Dr. Horkheimer received a total of $551 from 15 companies across 25 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Horkheimer's costs compare to other opticians in Little Silver?
Dr. Horkheimer's average Medicare payment per service is $27. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Horkheimer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Little Silver
Browse opticians in Little Silver ranked by procedure volume and transparency data.
Highest volume
Top Opticians in NJ
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in NJ
Which NJ opticians receive the most from drug and device companies.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology